The Danish-German Cardiogenic Shock trial found that men implanted with Johnson & Johnson’s Impella CP after experiencing a heart attack with cardiogenic shock gain 600 days of life, on average, compared to usual care at 10 years. The study demonstrated no benefit for women. Read More
Cyted Health Ltd. raised $44 million in a series B financing round to expand the reach of Endosign, its capsule sponge technology, in the U.S. Endosign is a minimally invasive device used to collect cell samples from the esophagus for the early detection of esophageal diseases, offering the potential to transform early cancer detection and improve health outcomes. Read More
The U.S. International Trade Commission advised the U.S. District Court for the District of Columbia that the court has no jurisdiction in an ongoing lawsuit between Masimo Inc. and Apple Inc. regarding the latter’s purportedly patent infringing digital health products. Read More
The U.K. Medicines and Healthcare Products Regulatory Agency announced a new pilot program for modifications to clinical trials that allows for automatic approvals of those changes based on the risks those changes present. Read More
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Brightheart, First Ascent, Iantrek, Inflammatix, Zoll. Read More
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Accelus, Alcon, Alpha Tau, Biotia, Care Advantage, Carenova, Congencia, Foresight Diagnostics, Highridge, Måna Care, Neurophet, Predicine, Roche, Seqone, Solventum, Staar Surgical, Themo Fisher Scientific. Read More
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Agilent, Coagusense, Geneseeq Technology, Hyperfine, Imperative Care. Read More
